Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

Conditions:   Spinal Cord Injuries;   Chronic Spinal Cord Injury;   Subacute Spinal Cord Injury Intervention:   Drug: NVG-291 Sponsor:   NervGen Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials